Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

NASDAQ: QNTM | CSE: QNTM | FRA: 0K91

Overview

Quantum BioPharma Ltd. announced its financial and operational results for the second quarter of 2026, ended June 30, 2026, according to the company. As of June 30, 2026, the company's combined cash and cash equivalents, and digital assets, totaled approximately US$9.5 million, an increase from US$4.1 million as of December 31, 2025. Assuming the current cash burn rate for the first half of 2026, management confirms that current liquidity is sufficient to fund planned operations to at least October 2027, according to the company.

Subsequent to quarter-end, the company received U.S. Food and Drug Administration (FDA) approval to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis, which the company describes as a pivotal regulatory milestone that advances its patented, first-in-class neuroprotective program into the next stage of clinical development.

Key Highlights

• Combined cash, cash equivalents, and digital assets of approximately US$9.5 million as of June 30, 2026, increased from US$4.1 million as of December 31, 2025.
• Cash and cash equivalents nearly doubled to US$3.65 million, up from US$1.91 million at December 31, 2025.
• Total shareholders' equity increased to US$6.09 million, up approximately 19% from US$5.10 million at December 31, 2025, according to the company.
• Working capital improved to approximately US$1.66 million as of June 30, 2026, up from approximately US$0.42 million at December 31, 2025, according to the company.
• Total operating expenses decreased by 53% in the second quarter of 2026 compared to the same period in 2025, to US$2.29 million from US$4.85 million.
• General and administrative expenses decreased by 47% in the second quarter of 2026 compared to the same period in 2025, to US$1.76 million from US$3.31 million.
• Cash used in operating activities fell 44% to US$3.46 million for the six months ended June 30, 2026, down from US$6.21 million in the same period of 2025.

Strategic/Operational Context

On August 10, 2026, subsequent to quarter-end, the company announced that the FDA had approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), clearing the company to advance its patented, first-in-class multiple sclerosis program into a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive MS. The company states this addresses an area of substantial unmet medical need within a global MS therapeutics market anticipated to reach approximately US$38.62 billion by 2030, citing Grand View Research, 2026.

Zeeshan Saeed, Chief Executive Officer of Quantum, said, "FDA clearance to proceed with our Lucid-MS Phase 2 trial is a transformative moment for Quantum and the result of years of dedicated scientific research." Donal Carroll, Chief Financial Officer of Quantum, said, "We brought total operating expenses down by more than 50% year-over-year in the second quarter, and our strengthened financial position assuming cash burn rate similar to the first half of 2026 provides a runway to at least October 2027 at our current budgeted spend."

Resources and Financials

• Current ratio: 1.2 as of June 30, 2026, compared to 1.07 as of December 31, 2025.
• Quick ratio: 1.19 as of June 30, 2026, compared to 1.06 as of December 31, 2025 (current assets excluding inventory and prepaid expenses, divided by current liabilities).
• Debt-to-Equity ratio: 1.36 as of June 30, 2026, compared to 1.19 as of December 31, 2025. Approximately 47% of current liabilities as of June 30, 2026 are associated with non-cash derivative fair value items, according to the company.

What to Watch Next

• Advancement of the randomized, double-blind, placebo-controlled Phase 2 clinical trial of Lucid-MS in patients with progressive multiple sclerosis, following FDA clearance of the company's IND application.
• The company's stated liquidity runway to at least October 2027, assuming a cash burn rate consistent with the first half of 2026.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. ("Unbuzzd") (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Read full press release here.

ArcStone Kingswood Growth Summit 2026

Join us September 16 at the Sheraton Centre Toronto for the 3rd Annual ArcStone Kingswood Growth Summit. A full day of fundraising, going-public, and cross-border listing conversations bringing together issuers, investors, and capital markets leaders. This is by invite-only gathering.

Register today to secure your personalized invitation

Disclaimer and Forward-Looking Statements

The information contained herein is provided by ArcStone Financial Pulse Inc. ("ArcStone Financial Pulse"), a subsidiary of ArcStone Securities and Investments Corp. ("ArcStone"), for informational purposes only. It is not, and under no circumstances should it be construed as, an offer to sell or a solicitation of an offer to buy any securities or other financial instruments in any jurisdiction. This content is not a research report within the meaning of FINRA Rules 2241 or 2242 and does not constitute a research report under any applicable securities laws.

Certain statements contained herein may constitute "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements are based on current expectations, estimates, and assumptions that involve known and unknown risks and uncertainties which may cause actual results or developments to differ materially from those expressed or implied. These statements often include words such as "anticipate," "believe," "expect," "intend," "may," "plan," "project," "should," "target," or similar expressions. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. Except as required by law, ArcStone undertakes no obligation to update or revise any forward-looking information.

This content is not intended as investment advice or a recommendation to buy or sell any security and does not take into account the investment objectives, financial situation, or needs of any individual. Investors should consult their own professional advisors before making any investment decisions.

ArcStone Securities and Investments Corp. is not a registered broker-dealer and does not provide investment advice or recommendations. All registrable activities in the United States are conducted through ArcStone Securities, LLC (CRD# 306029) and/or Kingswood Capital Partners, LLC (CRD# 288898), both FINRA-registered broker-dealers, members SIPC. ArcStone Canada Inc. is not registered as a dealer in any Canadian jurisdiction; registrable dealing activities in Canada are conducted through appropriately registered affiliates.

ArcStone Kingswood is a DBA Office of Supervisory Jurisdiction (OSJ) of Kingswood Capital Partners, LLC (Member FINRA/SIPC) under which registered representatives of ArcStone Securities, LLC (Member FINRA/SIPC) and registered representatives of Kingswood Capital Partners, LLC conduct joint capital markets and investment banking activities. ArcStone Securities, LLC and Kingswood Capital Partners, LLC are parties to a written agreement governing the sharing of fees on transactions in which registered representatives of both firms participate. All securities transactions and investment banking services described in this article are conducted exclusively through ArcStone Securities, LLC and/or Kingswood Capital Partners, LLC; "ArcStone Kingswood" itself is not a registered broker-dealer or separate legal entity.

ArcStone Financial Pulse Inc. is owned by the same parent entity (ArcStone Securities and Investments Corp.) that owns ArcStone Securities, LLC. This common ownership, together with the joint operating relationship between ArcStone Securities, LLC and Kingswood Capital Partners, LLC under the ArcStone Kingswood DBA OSJ banner, represents a structural conflict of interest. The issuer featured in this article (the "Company") may be a current or former client of ArcStone or any of its subsidiaries and affiliates. Where ArcStone or its subsidiaries and affiliates have received or have been promised consideration for services provided to the Company, such consideration may include cash, stock, stock options, warrants, and/or Restricted Stock Units (RSUs) for the provision of corporate advisory, investor relations, digital media, or capital markets consulting services. This relationship represents a potential conflict of interest, as ArcStone may be perceived to have an incentive to present the Company in a favorable light. The principals, directors, officers, employees, and related entities of ArcStone and its affiliates may, from time to time, own, buy, or sell securities or derivatives of the Company or its affiliates.